Comprehensive Care – difference and common aspects of acute treatment and chronic care

 

From Prof. Dr. Ley Sander, London, UK

 

Berlin (20. September 2008) – Epilepsy is the most common serious neurological disorder with a lifetime prevalence of between two and five percent. Many of those developing epilepsy do so at a young age.  The prevalence of active epilepsy (ie people with ongoing seizures) is up to one percent of the general population. For many people who develop epilepsy, the condition is short lived, but in about one fifth of those who develop epilepsy the condition becomes chronic with little prospect for full seizure remission.

 

Having recurrent epileptic seizures has implications in a number of life domains and these include education, employment, relationships, and leisure. The propensity to recurrent epileptic seizures may curtail someone’s independence and severely impact on quality of life. An acute epilepsy care model may be adequate in treating seizures acutely and may avoid direct medical complications but usually disregards these important aspects of a person’s life. On the other hand, a comprehensive care model provides a holistic approach to the person with the condition.

 

The delivery of comprehensive care involves a multidisciplinary team whilst acute care is usually based on physician only health delivery, focusing mainly on seizure control. This acute approach may well be adequate for those who have a short lived condition. Comprehensive care often involves voluntary agencies and support groups in addition to the multidisciplinary team. The team delivering comprehensive care usually consists of physicians of various disciplines (neurologists, paediatricians, neurophysiologists, neurosurgeons, psychiatrists, and learning disability specialists), epilepsy specialist nurses, therapists (speech, physio, occupational), social workers as well as counsellors. The team has access to full diagnostic facilities and well as to neurosurgical services. Comprehensive care is proactive and will engage in careful planning of a person’s management path. This is in contrast to acute care which is usually reactive and ad hoc. Comprehensive care is better placed to consider, for instance, the feasibility of epilepsy surgery in an individual person and to plan for it. It may also plan ahead for changes in life status of a person (for example, planned pregnancy).  People with well-controlled epilepsy may wish to taper or stop anti-epileptic drug therapy, and this should be the province of comprehensive care. This comprehensive care usually provides full information to the people it serves and will have an open access policy. Comprehensive epilepsy care also involves planned shared care with the primary care provider. There will be a shared-care protocol as well as guidelines for urgent access to the comprehensive care centre.

 

Despite the intuitive feeling that comprehensive care is better than acute care for people with epilepsy, there is no clear evidence to confirm this. Nevertheless, given the opportunity most people with epilepsy would prefer a comprehensive health delivery approach over the option of ad hoc management. A comprehensive approach usually provides continuity of care which is one of the features that people with epilepsy most appreciate in their assessment of health care delivery.

 

This presentation will discuss these issues, comparing and contrasting the acute care delivery approach to a full comprehensive care model for people with epilepsy.

 

Sander_1

 

Slide 1: Scope of epilepsy.

 

 

Sander_2

 

Slide 2: Compehensive care.

 

 

Sander_3

 

Slide 3: Comprehensive epilepsy care.

 

 

Sander_4

 

Slide 4: Comprehensive care better?

 

 

 


 

Source: 8th European Congress on Epiteptology, Satellite Symposium: “Comprehensive Care of Epilepsy in Europe”, Berlin, 20. September 2008 (Medizin und PR Kommunikation).

MEDICAL NEWS

Fitness watches generate useful information, but increase patient anxiety
A new device provides added protection against COVID-19 during endoscopic…
81 million Americans lacking space or bathrooms to follow COVID…
Front-line physicians stressed and anxious at work and home
EULAR: High-Dose Glucocorticoids and IL-6 Receptor inhibition can reduce COVID-19…

SCHMERZ PAINCARE

Morbus Fabry mittels Datenanalysen aus dem PraxisRegister Schmerz aufspüren
Neandertaler besaßen niedrigere Schmerzschwelle
Deutscher Schmerz- und Palliativtag 2020 – ONLINE
Deutsche Gesellschaft für Schmerzmedizin fordert Anerkennung von Nicht-Psychologen in der…
DBfK: Besondere Rolle für Pflegeexpert/innen Schmerz – nicht nur in…

DIABETES

“Körperstolz”: Michael Krauser managt seinen Diabetes digital
Der richtige Sensor – von Anfang an
Diabetes mellitus: Ein Risikofaktor für frühe Darmkrebserkrankungen
Fastenmonat Ramadan: Alte und neue Herausforderung für chronisch Erkrankte während…
Sanofi setzt sich für die Bedürfnisse von Menschen mit Diabetes…

ERNÄHRUNG

Corona-Erkrankung: Fehl- und Mangelernährung sind unterschätze Risikofaktoren
Gesundheitliche Auswirkungen des Salzkonsums bleiben unklar: Weder der Nutzen noch…
Fast Food, Bio-Lebensmittel, Energydrinks: neue Daten zum Ernährungsverhalten in Deutschland
Neue Daten zur Ernährungssituation in deutschen Krankenhäusern und Pflegeheimen: Mangelernährung…
Baxter: Parenterale Ernährung von Patienten mit hohem Aminosäurenbedarf

ONKOLOGIE

Darolutamid bei Prostatakarzinom: Hinweis auf beträchtlichen Zusatznutzen
Multiples Myelom: Wissenschaftler überprüfen den Stellenwert der Blutstammzelltransplantation
Neues zur onkologischen Supportiv- und Misteltherapie und aktuelle Kongress-Highlights zum…
Finanzierung der ambulanten Krebsberatung weiterhin nicht gesichert
Lungenkrebsscreening mittels Low-Dose-CT

MULTIPLE SKLEROSE

Geschützt: Multiple Sklerose: Novartis’ Siponimod verzögert Krankheitsprogression und Hirnatrophie bei…
Neurofilamente als Diagnose- und Prognosemarker für Multiple Sklerose
Bedeutung der Langzeittherapie bei Multipler Sklerose – mehr Sicherheit und…
Bristol Myers Squibb erhält Zulassung der Europäischen Kommission für Ozanimod…
Einige MS-Medikamente könnten vor SARS-CoV-2/COVID-19 schützen

PARKINSON

Neue Studie zur tiefen Hirnstimulation bei Parkinson-Erkrankung als Meilenstein der…
Putzfimmel im Gehirn
Parkinson-Patienten in der Coronakrise: Versorgungssituation und ein neuer Ratgeber
Neuer Test: Frühzeitige Differenzialdiagose der Parkinson-Erkrankung
Gegen das Zittern: Parkinson- und essentiellen Tremor mit Ultraschall behandeln…